CN115515601A - 用己糖型单糖及其类似物治疗病毒感染的方法 - Google Patents

用己糖型单糖及其类似物治疗病毒感染的方法 Download PDF

Info

Publication number
CN115515601A
CN115515601A CN202180032098.7A CN202180032098A CN115515601A CN 115515601 A CN115515601 A CN 115515601A CN 202180032098 A CN202180032098 A CN 202180032098A CN 115515601 A CN115515601 A CN 115515601A
Authority
CN
China
Prior art keywords
group
alkyl
hydrogen
coch
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180032098.7A
Other languages
English (en)
Chinese (zh)
Inventor
W·普里贝
I·弗科特
R·杰林斯基
S·斯科拉
D·皮克尔
W·克伦普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molekulin Biotechnology
University of Texas System
Original Assignee
Molekulin Biotechnology
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molekulin Biotechnology, University of Texas System filed Critical Molekulin Biotechnology
Publication of CN115515601A publication Critical patent/CN115515601A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180032098.7A 2020-03-16 2021-03-16 用己糖型单糖及其类似物治疗病毒感染的方法 Pending CN115515601A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990337P 2020-03-16 2020-03-16
US62/990,337 2020-03-16
PCT/US2021/022622 WO2021188586A1 (en) 2020-03-16 2021-03-16 Method of treating viral infections with hexose type monosaccharides and analogs thereof

Publications (1)

Publication Number Publication Date
CN115515601A true CN115515601A (zh) 2022-12-23

Family

ID=75439533

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180032098.7A Pending CN115515601A (zh) 2020-03-16 2021-03-16 用己糖型单糖及其类似物治疗病毒感染的方法

Country Status (11)

Country Link
US (1) US20230130134A1 (https=)
EP (1) EP4121060A1 (https=)
JP (1) JP2023518249A (https=)
KR (1) KR20220166800A (https=)
CN (1) CN115515601A (https=)
AU (1) AU2021239927A1 (https=)
BR (1) BR112022018536A2 (https=)
CA (1) CA3170872A1 (https=)
IL (1) IL296389A (https=)
MX (1) MX2022011488A (https=)
WO (1) WO2021188586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149388A (zh) * 2008-07-11 2011-08-10 得克萨斯系统大学评议会 具有抗癌活性的新型2-脱氧单糖乙酸酯
CN102388053A (zh) * 2009-04-03 2012-03-21 艾其林医药公司 作为抗感染剂的羟基噻吩并喹诺酮类及相关化合物
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
WO2019149436A1 (en) * 2018-01-30 2019-08-08 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
WO2004007747A2 (en) * 2002-07-12 2004-01-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assays for assembly of ebola virus nucleocapsids
WO2004062604A2 (en) 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
BRPI0708273A2 (pt) * 2006-02-24 2011-05-24 Univ Texas uso de compostos de hexoses
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149388A (zh) * 2008-07-11 2011-08-10 得克萨斯系统大学评议会 具有抗癌活性的新型2-脱氧单糖乙酸酯
CN102388053A (zh) * 2009-04-03 2012-03-21 艾其林医药公司 作为抗感染剂的羟基噻吩并喹诺酮类及相关化合物
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
WO2019149436A1 (en) * 2018-01-30 2019-08-08 Medizinische Universität Wien Medicament for prevention or treatment of rhinovirus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENISA BOJKOVA，等: "SARS-CoV-2 infected host cell proteomics reveal potential therapy targets", RESEARCH SQUARE, 11 March 2020 (2020-03-11), pages 2 - 3 *
NIEMANN H，等: "Coronavirus glycoprotein E1, a new type of viral glycoprotein", J MOL BIOL, vol. 153, no. 4, 25 December 1981 (1981-12-25), pages 993 - 1010 *

Also Published As

Publication number Publication date
AU2021239927A1 (en) 2022-10-06
BR112022018536A2 (pt) 2022-11-29
KR20220166800A (ko) 2022-12-19
MX2022011488A (es) 2023-03-01
JP2023518249A (ja) 2023-04-28
IL296389A (en) 2022-11-01
EP4121060A1 (en) 2023-01-25
CA3170872A1 (en) 2021-09-23
WO2021188586A1 (en) 2021-09-23
US20230130134A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
JP3548194B2 (ja) 過度のコラーゲン破壊を防止する薬剤
JP2014505058A (ja) 増殖性および炎症性皮膚疾患の治療用単糖ベース化合物
US20090054304A1 (en) Heterocyclic modulators of tgr5 for treatment of disease
US20110275577A1 (en) Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
CN115515601A (zh) 用己糖型单糖及其类似物治疗病毒感染的方法
US9714259B2 (en) Compositions and methods for improving glucose uptake
EP3134417B1 (en) Small molecule analogs of e4orf1
US20210322396A1 (en) Compositions with synergistic permeation enhancers for drug delivery
JP2016510332A (ja) 治療配合物（ｃｏｍｐｏｕｎｄｓ）
WO2020055916A9 (en) Dithiolsaccharide mucolytic agents and uses thereof
EP2981270B1 (en) Esters of 2-deoxy-monosaccharides with anti proliferative activity
EP4188348A1 (en) Thermo-sensitive permeation enhancing formulations for drug delivery
NL2031331B1 (en) Transmucosal delivery of a short-acting psychedelic compound
JP2001270826A (ja) 皮膚疾患治療・予防用外用剤
HK1214267B (en) Compositions and methods for improving glucose uptake
HK1235406A1 (en) Small molecule analogs of e4orf1
HK1235406B (en) Small molecule analogs of e4orf1
JPH0892089A (ja) ドライバジャイナ治療剤
WO2017070235A1 (en) Antitussive compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination